Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135].
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Contusugene ladenovec (Primary) ; Contusugene ladenovec (Primary)
- Indications Head and neck cancer; Mouth disorders; Pharyngeal disorders
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 22 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov (NCT00064103).
- 22 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov (NCT00064103).
- 29 Nov 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov. (NCT00410865).